WINTON GROUP Ltd Has $5.15 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

WINTON GROUP Ltd lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 169.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,550 shares of the life sciences company’s stock after buying an additional 24,249 shares during the period. WINTON GROUP Ltd’s holdings in Illumina were worth $5,151,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Versant Capital Management Inc boosted its position in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares during the last quarter. Golden State Wealth Management LLC acquired a new position in Illumina during the fourth quarter worth $32,000. Assetmark Inc. grew its position in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Illumina in the 4th quarter valued at $45,000. Finally, Lee Danner & Bass Inc. bought a new stake in Illumina during the 4th quarter worth about $48,000. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ILMN. Morgan Stanley decreased their price objective on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. Guggenheim lowered their price target on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Piper Sandler increased their price objective on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Hsbc Global Res downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. Finally, Canaccord Genuity Group dropped their price target on shares of Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $140.90.

Illumina Stock Down 5.4 %

ILMN stock opened at $82.83 on Thursday. Illumina, Inc. has a fifty-two week low of $80.18 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The stock has a market capitalization of $13.12 billion, a price-to-earnings ratio of -10.79, a PEG ratio of 1.60 and a beta of 1.17. The business’s fifty day moving average price is $105.03 and its two-hundred day moving average price is $127.40.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.